Opinion|Videos|May 19, 2025
Post Hoc Analysis of ARANOTE; Ultra-Low PSA Responses
Author(s)Neal Shore, MD, FACS
Research highlights the significant benefits of achieving ultra-low PSA levels in metastatic hormone-sensitive prostate cancer, delaying disease progression effectively.
Advertisement
Episodes in this series
Rationale for Ultra-Low PSA Threshold Analysis
Key Themes:
- Post hoc analysis focusing on PSA response thresholds
- Particular focus on ultra-low PSA threshold (<0.02 ng/mL)
- PSA as a surrogate biomarker in advanced prostate cancer
Expert Insights:
- Dr Shore explained the rationale for examining the ultra-low PSA threshold of <0.02 ng/mL in the ARANOTE trial.
The discussion highlighted the historical relevance of low PSA levels in predicting treatment outcomes and the potential increased sensitivity of this threshold.
Advertisement
Related to this article
An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.
In RTOG 3506, adding enzalutamide to standard ADT and salvage radiotherapy was associated with 2-year PFS benefit.
In the phase 3 PACE-A trial, SBRT and prostatectomy showed similar 8-year disease control in localized prostate cancer, with lower rates of urinary incontinence after SBRT.
Using PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.
The registrational study is designed to evaluate the diagnostic performance of 68Ga-DOTA-RM2 vs histopathology in prostate cancer.
Advertisement
Advertisement
Trending on Urology Times
1
Avoiding False Positives on Prostate Cancer PSMA PET Scans
2
2026 AUA/SUO NMIBC guideline: Key updates for clinical practice
3
Decipher may help identify ADT benefit in intermediate-risk prostate cancer
4
AUA South Central Section Meeting: Mark D. Tyson, II, MD, MPH, recaps data in NMIBC
5